VirTus develops new COVID-19 serology testing service

We are delighted to announce our new testing service for COVID-19

Click to find out more

About us

Our Services

Pre-clinical studies

Contact

Follow us

Contact

Our services

We perform state of the art preclinical and clinical research studies in respiratory infections and airway diseases...

Find out more

Our team

Virtus’s Founders have worked together since 2001 in various academic and commercial settings.

Professor Sebastian Johnston

Director & Chief Medical Officer

Dr Michael R Edwards

Managing & Scientific Director

Meet the full team

Infection rate

The overall infection rate of our current stock of rhinovirus is 82% in asthmatics, COPD and healthy volunteers.

Source : Deloitte 2015

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Our Vision

We perform state of the art preclinical and clinical research studies in respiratory infections and airway diseases...

Learn more